Effects of Ranibizumab, Bevacizumab, and Aflibercept on Senescent Retinal Pigment Epithelial Cells
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Anti-vascular endothelial growth factor (VEGF) agents have been used for the last 10 years, but their safety profile, including cytotoxicity against various ocular cells such as retinal pigment epithelial (RPE) cells, remains a serious concern. Safety studies of VEGF agents conducted to date have primarily relied on healthy RPE cells. In this study, we assessed the safety of three anti-VEGF agents, namely, ranibizumab, bevacizumab, and aflibercept, on senescent RPE cells. Methods: Senescent human induced pluripotent stem cell-derived RPE cells were generated by continuous replication and confirmed with senescence biomarkers. The viability, proliferation, protein expression, and phagocytosis of the senescent RPE cells were characterized 3 days after anti-VEGF treatment with clinical doses of ranibizumab, bevacizumab, or aflibercept. Results: Clinical doses of ranibizumab, bevacizumab, or aflibercept did not decrease the viability or alter proliferation of senescent RPE cells. In addition, the anti-VEGF agents did not induce additional senescence, impair the protein expression of zonula occludens-1 and RPE65, or reduce the phagocytosis capacity of senescent RPE cells. Conclusions: Clinical dosages of ranibizumab, bevacizumab, or aflibercept do not induce significant cytotoxicity in senescent RPE cells.
Abstract
Purpose: Anti-vascular endothelial growth factor (VEGF) agents have been used for the last 10 years, but their safety profile, including cytotoxicity against various ocular cells such as retinal pigment epithelial (RPE) cells, remains a serious concern. Safety studies of VEGF agents conducted to date have primarily relied on healthy RPE cells. In this study, we assessed the safety of three anti-VEGF agents, namely, ranibizumab, bevacizumab, and aflibercept, on senescent RPE cells. Methods: Senescent human induced pluripotent stem cell-derived RPE cells were generated by continuous replication and confirmed with senescence biomarkers. The viability, proliferation, protein expression, and phagocytosis of the senescent RPE cells were characterized 3 days after anti-VEGF treatment with clinical doses of ranibizumab, bevacizumab, or aflibercept. Results: Clinical doses of ranibizumab, bevacizumab, or aflibercept did not decrease the viability or alter proliferation of senescent RPE cells. In addition, the anti-VEGF agents did not induce additional senescence, impair the protein expression of zonula occludens-1 and RPE65, or reduce the phagocytosis capacity of senescent RPE cells. Conclusions: Clinical dosages of ranibizumab, bevacizumab, or aflibercept do not induce significant cytotoxicity in senescent RPE cells.
참고문헌 (31)
- Fine SL, "Age-related macular degeneration", N Engl J Med, 342, pp.483~492 (2000)[DOI]
- Kliffen M, "Increased expression of angiogenic growth factors in age-related maculopathy", Br J Ophthalmol, 81, pp.154~162 (1997)[DOI]
- Rakic JM, "Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization", Invest Ophthalmol Vis Sci, 44, pp.3186~3193 (2003)[DOI]
- Kozlowski MR, "RPE cell senescence: a key contributor to age-related macular degeneration", Med Hypotheses, 78, pp.505~510 (2012)[DOI]
- Marazita MC, "Oxidative stress-induced premature senescence dysregulates VEGF and CFH expression in retinal pigment epithelial cells: implications for age-related macular degeneration", Redox Biol, 7, pp.78~87 (2016)[DOI]
- Mishima K, "Senescence-associated beta-galactosidase histochemistry for the primate eye", Invest Ophthalmol Vis Sci, 40, pp.1590~1593 (1999)
- Brown DM, "R anibizumab versus verteporfin for neovascular age-related macular degeneration", N Engl J Med, 355, pp.1432~1444 (2006)[DOI]
- Rosenfeld PJ, "Ranibizumab for neovascular age-related macular degeneration", N Engl J Med, 355, pp.1419~1431 (2006)[DOI]
- Yoganathan P, "Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration", Retina, 26, pp.994~998 (2006)[DOI]
- Aggio F B, "Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments", Graefes Arch Clin Exp Ophthalmol, 245, pp.215~220 (2007)[DOI]
- Heier JS, "Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration", Ophthalmology, 119, pp.2537~2548 (2012)[DOI]
- Talks JS, "First-year visual acuity outcomes of providing aflibercept according to the VIEW study protocol for age-related macular degeneration", Ophthalmology, 123, pp.337~343 (2016)[DOI]
- Malik D, "Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture", Br J Ophthalmol, 98(Suppl 1), pp.i11~i16 (2014)[DOI]
- Schnichels S, "Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells", Br J Ophthalmol, 97, pp.917~923 (2013)[DOI]
- Ammar DA, "The effects of aflibercept on the viability and metabolism of ocular cells in vitro", Retina, 33, pp.1056~1061 (2013)[DOI]
- Brar VS, "Evaluation of differential toxicity of varying doses of bevacizumab on retinal ganglion cells, retinal pigment epithelial cells, and vascular endothelial growth factor-enriched choroidal endothelial cells", J Ocul Pharmacol Ther, 25, pp.507~511 (2009)[DOI]
- Klettner A, "Effects of aflibercept on primary RPE cells: toxicity, wound healing, uptake and phagocytosis", Br J Ophthalmol, 98, pp.1448~1452 (2014)[DOI]
- Saenz-de-Viteri M, "Single- and repeated-dose toxicity study of bevacizumab, ranibizumab, and aflibercept in ARPE-19 cells under normal and oxidative stress conditions", Biochem Pharmacol, 103, pp.129~139 (2016)[DOI]
- Spitzer MS, "Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells", Br J Ophthalmol, 90, pp.1316~1321 (2006)[DOI]
- Grunwald JE, "Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials", Ophthalmology, 122, pp.809~816 (2015)[DOI]
- Grunwald JE, "Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials", Ophthalmology, 121, pp.150~161 (2014)[DOI]
- Zhu Y, "Three-dimensional neuroepithelial culture from human embryonic stem cells and its use for quantitative conversion to retinal pigment epithelium", PLoS One, 8, pp.e54552~ (2013)[DOI]
- Lin H, "Integrin alphavbeta5 participates in the binding of photoreceptor rod outer segments during phagocytosis by cultured human retinal pigment epithelium", Invest Ophthalmol Vis Sci, 39, pp.1703~1712 (1998)
- Kuilman T, "The essence of senescence", Genes Dev, 24, pp.2463~2479 (2010)[DOI]
- Rufini A, "Senescence and aging: the critical roles of p53", Oncogene, 32, pp.5129~5143 (2013)[DOI]
- Harley CB, "Telomeres shorten during ageing of human fibroblasts", Nature, 345, pp.458~460 (1990)[DOI]
- Zhu H, "Healthy aging and disease: role for telomere biology?", Clin Sci (Lond), 120, pp.427~440 (2011)[DOI]
- Kokkinaki M, "Human induced pluripotent stem-derived retinal pigment epithelium (RPE) cells exhibit ion transport, membrane potential, polarized vascular endothelial growth factor secretion, and gene expression pattern similar to native RPE", Stem Cells, 29, pp.825~835 (2011)[DOI]
- Ford KM, "Expression and role of VEGF in the adult retinal pigment epithelium", Invest Ophthalmol Vis Sci, 52, pp.9478~9487 (2011)[DOI]
- Kurihara T, "Targeted deletion of Vegfa in adult mice induces vision loss", J Clin Invest, 122, pp.4213~4217 (2012)[DOI]
- Rofagha S, "Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)", Ophthalmology, 120, pp.2292~2299 (2013)[DOI]